PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Autor: Loverix L., Vergote I., Busschaert P., Vanderstichele A., Venken T., Boeckx B., Harter P., Brems H., Van Nieuwenhuysen E., Pignata S., Baert T., Gonzalez-Martin A., Han S., Marth C., Neven P., Colombo N., Berteloot P., Mäenpää J., Olbrecht S., Laga T., Sablon E., Ray-Coquard I., Pujade-Lauraine E., Lambrechts D., Van Gorp T.

Publikováno v: European Journal of Cancer. 188:131-139

Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLU

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1bebb5507e5fc841665cd1eced0e3a9
https://doi.org/10.1016/j.ejca.2023.04.020

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

545P - Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials

Autor: Montagut, C., Alonso, V., Escudero, P., Fernández-Martos, C., Salud Salvia, A., Méndez, M., Gallego Plazas, J., Rodriguez, J.R., Martín-Richard, M., Fernández-Plana, J., Aparicio, J., Feliu Batlle, J., García de Albéniz, X., Rojo, F., Fernández, V., Claes, B., Maertens, G.G., Sablon, E., Jacobs, B.A.W., Maurel, J.

Publikováno v: In Annals of Oncology October 2018 29 Supplement 8

697P - Detection of microsatellite instability (MSI) with a novel panel of biomarkers in gastric cancer samples

Autor: De Craene, B., Feng, Z., Rondelez, E., Vandenbroeck, L., Peeters, K., Maertens, G., Sablon, E., Cai, T.

Publikováno v: In Annals of Oncology September 2017 28 Supplement 5:v237-v237

The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation

Autor: França,P.H.C., Coelho,H.S.M., Brandão,C.E., Segadas,J.A., Quintaes,R.F., Carrilho,F.J., Ono-Nita,S., Mattos,A.A., Tovo,C., Gouvea,V.S., Sablon,E., Vanderborght,B.O.M.

Publikováno v: Brazilian Journal of Medical and Biological Research, Volume: 40, Issue: 12, Pages: 1605-1614, Published: 29 OCT 2007
Brazilian Journal of Medical and Biological Research, Vol 40, Iss 12, Pp 1605-1614 (2007)
Brazilian Journal of Medical and Biological Research v.40 n.12 2007
Brazilian Journal of Medical and Biological Research
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC

Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ffe29e29a65081324e7fa971841bea1a
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003&lng=en&tlng=en